Which of the following medications—Glyxambi (dapagliflozin/linagliptin), metformin, colostrum, repaglinide, rosuvastatin, insulin, and lisinopril—is most likely responsible for a rash, and how should it be managed?

Lisinopril is the Most Likely Culprit for the Rash

Among the medications listed, lisinopril (an ACE inhibitor) is the most probable cause of the rash and should be discontinued immediately, with close monitoring for angioedema or other severe hypersensitivity reactions. ACE inhibitors are well-established causes of various cutaneous reactions including maculopapular rash, urticaria, and potentially life-threatening angioedema.

Ranking the Suspects by Likelihood

High Probability Culprits

Lisinopril stands out as the primary suspect because:

• ACE inhibitors commonly cause cutaneous hypersensitivity reactions
• Rash can occur at any point during therapy (early or delayed)
• May herald more serious reactions like angioedema
• Well-documented in clinical practice as a frequent offender

Glyxambi (empagliflozin/linagliptin) is the second most likely cause:

• FDA labeling explicitly lists "skin reactions (e.g., rash, urticaria)" as postmarketing adverse reactions 1
• Bullous pemphigoid has been reported with empagliflozin 1
• Hypersensitivity reactions including rash occur in approximately 4.5% of patients on dapagliflozin (similar SGLT2 inhibitor) 2
• Recent case reports document Sweet's syndrome with dapagliflozin 3

Moderate Probability

Metformin can cause rash but is uncommon:

• Erythema multiforme has been documented, though rare 4
• Leukocytoclastic vasculitis reported in isolated cases 5
• Generally considered to have favorable tolerability profile
• Cutaneous reactions are infrequent enough to warrant case reports

Repaglinide has documented hypersensitivity potential:

• Maculopapular rash reported with delayed onset (3-5 days after initiation) 6
• Type IV hypersensitivity mechanism suggested 6
• Less commonly prescribed, so fewer reports overall

Low Probability

Rosuvastatin: Statins rarely cause rash as an isolated finding without myopathy symptoms

Insulin: Cutaneous reactions typically occur at injection sites (lipohypertrophy, lipoatrophy), not generalized rash

Colostrum: Not a pharmaceutical agent; minimal allergenic potential unless patient has specific dairy protein allergy

Management Algorithm

Immediate Actions

1. Assess severity first: Examine for bullae, mucosal involvement, skin sloughing, or systemic symptoms (fever, lymphadenopathy)

   • If present → Stop ALL medications immediately and consider Stevens-Johnson syndrome/TEN
   • If absent → proceed with systematic evaluation

2. Check for angioedema: Examine lips, tongue, face, and airway

   • If present with lisinopril use → Discontinue permanently, never rechallenge
   • Consider C1 esterase inhibitor levels if recurrent

3. Document rash characteristics:

   • Distribution (generalized vs. localized)
   • Morphology (maculopapular, urticarial, targetoid, purpuric)
   • Timing relative to medication initiation

Systematic Discontinuation Strategy

For mild-to-moderate rash without severe features:

1. Discontinue lisinopril first (highest probability, most critical to identify)

   • Monitor for 7-14 days
   • If rash resolves → lisinopril was the culprit; switch to ARB (losartan, valsartan)
   • If rash persists → proceed to step 2

2. Discontinue Glyxambi second (next highest probability)

   • Continue metformin alone for glycemic control
   • Monitor for 7-14 days
   • If rash resolves → empagliflozin or linagliptin was responsible
   • Consider alternative SGLT2 inhibitor cautiously or switch to DPP-4 inhibitor alone

3. If rash persists, evaluate repaglinide and metformin

   • Temporarily discontinue both
   • Use insulin for glycemic control during evaluation period
   • Reintroduce one at a time after rash clears

Critical Pitfalls to Avoid

• Do not continue lisinopril if angioedema develops: This can be fatal; ACE inhibitor-induced angioedema may occur years into therapy
• Do not assume SGLT2 inhibitors are innocent: The FDA label explicitly warns of bullous pemphigoid and hypersensitivity reactions 1
• Do not stop all diabetes medications simultaneously unless severe reaction: This creates dangerous hyperglycemia
• Do not rechallenge with the suspected culprit without dermatology/allergy consultation if the reaction was severe

Symptomatic Management

While identifying the culprit:

• Topical corticosteroids (triamcinolone 0.1% or betamethasone) for localized rash
• Oral antihistamines (cetirizine 10 mg daily or hydroxyzine 25-50 mg TID) for pruritus
• Systemic corticosteroids (prednisone 0.5-1 mg/kg/day) only if severe or progressive despite drug discontinuation

Long-Term Considerations

If lisinopril is confirmed as the cause:

• Switch to angiotensin receptor blocker (ARB) - cross-reactivity with rash is uncommon (unlike angioedema where caution is needed)
• Document allergy clearly in medical record

If Glyxambi is confirmed:

• Consider whether SGLT2 inhibitor or DPP-4 inhibitor was responsible
• May trial alternative agents from different class
• The cardiovascular and renal benefits of SGLT2 inhibitors may warrant cautious rechallenge with different agent under supervision if reaction was mild

If metformin is confirmed:

• This significantly limits diabetes treatment options
• Consider GLP-1 receptor agonists as alternative first-line therapy
• Document carefully as metformin is cornerstone of T2DM management